Table 2.
Treatment | Exploration trial (day 1) | Exploration trial (day 2) | Exploration trial (day 3) |
---|---|---|---|
Control | 19.3 ± 0.95∗∗ | 17.16 ± 1.54∗∗ | 12.67 ± 1.31∗∗ |
Saline control | 20.6 ± 1.28∗∗ | 16.00 ± 2.71∗∗ | 14.10 ± 1.92∗∗ |
Scopolamine | 37.3 ± 2.55b | 33.5 ± 1.88b | 30.67 ± 1.85b |
Lisinopril (0.225 mg/kg) + scopolamine | 39.5 ± 2.91b | 38.22 ± 1.03b | 27.50 ± 2.46b |
Lisinopril (0.45 mg/kg) + scopolamine | 34.75 ± 1.88b | 31.00 ± 2.71b | 25.21 ± 1.18b,∗ |
Fosinopril (0.90 mg/kg) + scopolamine | 35.75 ± 2.78b | 36.0 ± 2.92b | 25.50 ± 1.08b,∗ |
Fosinopril (1.80 mg/kg) + scopolamine | 34.00 ± 3.02b | 28.75 ± 2.45a,∗ | 19.75 ± 1.26a,∗ |
Comparison between control, scopolamine, lisinopril, and fosinopril during the exploration trials in passive avoidance test. Values are mean ± SE, ∗versus scopolamine (p < 0.05), ∗∗versus scopolamine (p < 0.001), aversus control (p < 0.05), and bversus control (p < 0.001).